Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$0.66 +0.01 (+1.54%)
Closing price 03:53 PM Eastern
Extended Trading
$0.67 +0.01 (+1.41%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRAX vs. AEON, IMCC, BFRI, SNPX, CARM, INAB, KALA, PHXM, ERNA, and RNAZ

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include AEON Biopharma (AEON), IM Cannabis (IMCC), Biofrontera (BFRI), Synaptogenix (SNPX), Carisma Therapeutics (CARM), IN8bio (INAB), KALA BIO (KALA), PHAXIAM Therapeutics (PHXM), Ernexa Therapeutics (ERNA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs. Its Competitors

AEON Biopharma (NASDAQ:AEON) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Virax Biolabs Group has higher revenue and earnings than AEON Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$6.08-0.19
Virax Biolabs Group$10K286.74-$6.06MN/AN/A

Virax Biolabs Group has a consensus price target of $3.00, indicating a potential upside of 354.06%. Given Virax Biolabs Group's higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Virax Biolabs Group
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

AEON Biopharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

In the previous week, Virax Biolabs Group had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Virax Biolabs Group and 1 mentions for AEON Biopharma. Virax Biolabs Group's average media sentiment score of 0.95 beat AEON Biopharma's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company Overall Sentiment
AEON Biopharma Neutral
Virax Biolabs Group Positive

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 0.9% of AEON Biopharma shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
Virax Biolabs Group N/A N/A N/A

Summary

Virax Biolabs Group beats AEON Biopharma on 8 of the 10 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.83M$3.36B$6.06B$10.53B
Dividend YieldN/A2.31%5.73%4.79%
P/E RatioN/A7.9164.4523.40
Price / Sales286.74473.61593.63135.47
Price / CashN/A46.9537.5761.53
Price / Book0.5210.4312.676.74
Net Income-$6.06M-$52.58M$3.32B$276.59M
7 Day Performance3.07%0.98%0.50%0.86%
1 Month Performance10.86%14.76%9.42%8.17%
1 Year Performance-63.50%21.29%79.11%43.66%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
3.0064 of 5 stars
$0.66
+1.5%
$3.00
+354.1%
-63.6%$2.83M$10K0.005Analyst Forecast
AEON
AEON Biopharma
0.9291 of 5 stars
$0.94
+10.0%
N/A-98.5%$10.89MN/A5.205Gap Down
IMCC
IM Cannabis
0.6528 of 5 stars
$2.02
-2.4%
N/A-13.7%$10.86M$39.44M-3.74340
BFRI
Biofrontera
2.3763 of 5 stars
$1.03
-3.3%
$2.75
+168.3%
+17.8%$10.75M$37.32M0.0070
SNPX
Synaptogenix
N/A$7.71
+20.3%
N/A+132.8%$10.72MN/A-0.764Gap Up
CARM
Carisma Therapeutics
2.4757 of 5 stars
$0.26
+2.5%
$1.93
+633.6%
-95.1%$10.70M$19.63M-0.1720Gap Up
INAB
IN8bio
2.6055 of 5 stars
$2.46
+4.7%
$180.00
+7,217.1%
-67.9%$10.67MN/A-0.2720News Coverage
Analyst Forecast
KALA
KALA BIO
4.1163 of 5 stars
$1.64
+7.9%
$20.38
+1,142.4%
-71.7%$10.67M$3.89M-0.2430
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58MN/A0.0049
ERNA
Ernexa Therapeutics
1.046 of 5 stars
$1.31
-3.7%
N/A-91.7%$10.43M$580K0.0010Gap Down
RNAZ
TransCode Therapeutics
2.1797 of 5 stars
$11.94
+1.2%
$280.00
+2,245.3%
-99.9%$9.84MN/A0.009News Coverage

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners